A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.
Brachytherapy(2018)
摘要
Degarelix is effective for prostate downsizing before prostate brachytherapy with a median volume decrease of 26.2% by 8 weeks. Despite the short course of treatment and eventual testosterone recovery, follicle-stimulating hormone and luteinizing hormone remain elevated beyond 12 months. Further investigation with randomized comparisons to other hormonal agents is warranted.
更多查看译文
关键词
Prostate neoplasms,Degarelix,Brachytherapy,Testosterone,Quality of life
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络